AlphaNa Bioscience
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
Corporate information
- Company entity
- AlphaNa Bioscience
- Headquarters / principal office
- No verified public location identified
- Founded
- 2021 (Hefei entity); Shanghai entity 2024 ↗
- Ownership / capital status
- PrivateSeries A (2026; amount undisclosed) ↗
- Official corporate reference
- https://www.alphanabio.com/?c=9 ↗
- Latest financing / award identified
- 2026 · Series A · Undisclosed ↗
- LinkedIn company page
- Independent company page not verified
Per the 2026 English company timeline; no day or amount is inferred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- AlphaNa Bioscience — primary program / ownership disclosure
- Founding / incorporation disclosure — scope stated in field
- Corporate ownership / financing disclosure